Top news of the week: 18.02.2020.
#biospace #lifesciences #pharma #valentinesday #biotech #sequencing
Companies And Industries
Chutes & Ladders—Ex-Pfizer R&D head Abraham joins Vividion https://t.co/dLXz5TXdCB https://t.co/xssHhQyg02
OpenChutes & Ladders—Ex-Pfizer R&D head Abraham joins Vividion
Vividion nabs ex-Pfizer R&D head Abraham; Lu takes CMO role at Pharvaris; Enterprise taps Morris as medical head.
He "retired" last year, leaving Pfizer as its head of cancer R&D; now, he's returned to research at a much smaller outfit. https://t.co/XwxlZ8a6WT
OpenEx-Pfizer oncology R&D lead lands at Fierce 15 winner Vividion Therapeutics
Pfizer’s longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech.
Valentine’s Day Matters of the Heart, Biopharma-Style
#biospace #lifesciences #valentinesday #biotech #pharma
https://t.co/LmjhDMznXF
OpenValentine’s Day Matters of the Heart, Biopharma-Style
There is a significant amount of work being done on cardiovascular diseases. Here’s a look at just some of the recent news.
The Dish’s Weekly Biotechnology News Wrap Up – February 7, 2020
*|RSSFEED:DATE|* Incase you missed it. We summarize the week's top biotechnology stories.
“You have simple to use, cost-effective technology that is PCR, but you don’t have the precision. And on the other hand, you have #sequencing, which is a very high end, very powerful tool, but is really high-cost. Digital PCR can fill the gap.” @StillaTech
https://t.co/COREfzHwFB
OpenFrench Biotech Raises €20M to Make Precision Molecular Diagnostics
Stilla Technologies has raised a €20M Series C round to fund its mission to produce next-generation microchips that make molecular diagnostics more precise and user-friendly than currently ...
Trials flops see Pfizer cut GylcoMimetics pact, Merck ax KalVista research deal https://t.co/wRmyAauzTF https://t.co/m7MJhrs8N6
OpenTrial flops see Pfizer cut GlycoMimetics pact, Merck ax KalVista research deal
Two Big Pharmas have decided to walk away from two small biotech deals after disappointing trial results: Pfizer from GlycoMimetics and Merck from KalVista Pharmaceuticals.
Biotech firms consider contingency plans as the coronavirus outbreak hits CROs by @lisamjarvis. https://t.co/h3iblYWRjR
OpenBiotech firms consider contingency plans as the coronavirus outbreak hits CROs
The industry’s reliance on China-based firms for chemistry services is in the spotlight
LogicBio rocked by FDA clinical hold on genome editing trial https://t.co/j9txFBvBPO https://t.co/djRBguIYc8
OpenLogicBio rocked by FDA clinical hold on genome editing trial
The FDA has placed a clinical hold on LogicBio Therapeutics’ planned genome editing trial. LogicBio wants to trial the therapy in methylmalonic acidemia patients aged two years and up but ...